Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
Paris (ots/PRNewswire) - Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life, to develop ...
Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...
Paris (ots/PRNewswire) - - Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales - Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) - Important developments in oncology to address high unmet medical ...
Paris (ots/PRNewswire) - - A new ambition by 2030 to accelerate its transformation dynamic - A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to accelerate its transformation dynamics in order ...
Paris (ots/PRNewswire) - - Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerated oncology strategy with the acquisition of ...
Paris and Boston (ots/PRNewswire) - - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug ...
Mechelen, Belgium and Paris (ots/PRNewswire) - Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three ...
Thousand Oaks, Calif., South San Francisco, Calif., and Suresnes, France (ots/PRNewswire) - - Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events - Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death - Results Will Be Presented in Late Breaking ...
Prague, Czech Republic (ots/PRNewswire) - "Early Diagnosis and Treatment of Chronic Venous Disease are Mandatory to Prevent Progression to More Severe Clinical Stages Including Venous Ulcers" The VEIN CONSULT Program, the largest ever epidemiological survey in chronic venous disease carried out under the auspices of ...
Paris (ots/PRNewswire) - - Positive Correlation Established Between Valdoxan's Efficacy and Disease Severity New data, presented today at the 24th European College of Neuropsychopharmacology (ECNP) Congress, further highlight the distinctive profile of efficacy of Valdoxan(R) (agomelatine) in the treatment of ...
Paris (ots/PRNewswire) - - For The First Time: Direct Link Found Between Reducing Heart Rate and Quality of Life New results from SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), the largest-ever morbi-mortality study of treatments for chronic heart failure, reveal for the first time a direct link between heart rate reduction and quality ...
Rome, June 19, 2010 (ots/PRNewswire) - /OFF HOLD OFF HOLD OFF HOLD - Servier, PIV395527 The following release: "Protelos(R) (Strontium Ranelate) Builds Stronger Bone Compared to Bisphosphonates" is now OFF HOLD. Distribution time: 19 Jun 2010 08:15 GMT The osteoporosis treatment Protelos(R) (strontium ranelate, Servier) has greater effects than the commonly prescribed bisphosphonate alendronate on bone ...
Paris (ots/PRNewswire) - - New Analysis of ASCOT-BPLA Data Identifies Major Predictors of NOD Among Hypertensives A new analysis of data from the landmark Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA) published today in Diabetes Care has identified the major predictors of new-onset diabetes (NOD) in patients with ...
Vienna, Austria (ots/PRNewswire) - Valdoxan(R) (agomelatine), the first melatonergic antidepressant, is an effective, long-term treatment for Major Depressive Disorder (MDD) according to new data presented today at the European College of Neurospsychopharmacology (ECNP) annual congress. The new international ...
Honolulu, Hawaii (ots/PRNewswire) - - Protelos(R) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos(R) (strontium ranelate) stimulates bone formation and increases bone volume by 30% in high fracture risk patients who have been on long term ...
Copenhagen, Denmark (ots/PRNewswire) - - New Data Show Clear Benefit of Protelos(R) in Wide Range of Osteoporosis Patients Irrespective of Disease Severity New, long term data presented at the 34th European Symposium on Calcified Tissues (ECTS) this week underscore the unmatchable, long-term efficacy and ...
Barcelona, Spain (ots/PRNewswire) - - Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl(R) (perindopril) provides a number of clinical benefits to elderly people with chronic heart failure according to the results of a study presented at ...
Vienna, Austria (ots/PRNewswire) - - New Data Demonstrate "Unique", Five Year Anti-Osteoporotic Efficacy Against Both Vertebral and Non-Vertebral Fractures New five year data presented at the 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO 6) meeting today show that the new osteoporosis treatment Protelos(R) ...
Paris, November 16 (ots/PRNewswire) - - Emea Approves New Treatment for Chronic Stable Angina Procoralan (ivabradine, Servier), the first selective and specific If inhibitor, has received marketing authorization in 27 European countries from the European Medicines Evaluation Agency (EMEA) for the ...
Dallas, Texas, November 14 (ots/PRNewswire) - - CAFÉ Study Shows Central Aortic Pulse Pressure Important Determinant of Cardiovascular Outcomes A new sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)(1), presented during a late breaking clinical trial session of the American Heart ...
Amsterdam, The Netherlands (ots/PRNewswire) - - Valdoxan(R) (agomelatine) Provides Antidepressant Efficacy With the Additional Clinical Benefit of Sleep Improvement With no Effect on Daytime Vigilance The first melatonergic antidepressant, Valdoxan(R) (agomelatine), offers an innovative new approach to the treatment of depression. Valdoxan combines ...